Phase 3 Tuberculosis Trial, Recruiting NCT07152639 Sponsor: Chengdu CoenBiotech Co., Ltd Condition: Tuberculosis
Back to Tuberculosis

Phase 3 Tuberculosis Trial, Recruiting

NCT07152639
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

General community members (no tuberculosis history):

  • People aged 3 years or older, of any gender
  • People (or their guardian) who agree to take part and sign a consent form
  • People (or their guardian) who are able to attend follow-up visits as required by the trial
  • People with no history of tuberculosis (TB), whether affecting the lungs or other parts of the body
  • People with no current TB-related symptoms — such as ongoing tiredness, mild fever in the afternoons, loss of appetite, night sweats, cough, chest pain, or chest tightness (for women, this also includes no unexplained changes to menstrual cycles)
  • For a specific sub-group called the "triple-negative population": people whose results from two skin tests (one on each arm) and a blood test called IGRA all come back negative

People diagnosed with tuberculosis (including lung TB):

  • People aged 3 years or older, of any gender
  • Adults (18 and over) diagnosed with TB or lung TB according to the relevant Chinese national diagnostic standard; children aged 3–17 diagnosed with TB according to the relevant Chinese expert consensus guidelines
  • This includes TB affecting the lungs or other parts of the body, and both new and returning cases
  • People (or their guardian) who agree to take part and sign a consent form
  • People (or their guardian) who are able to attend follow-up visits as required by the trial

People diagnosed with a lung disease that is not tuberculosis:

  • People with a confirmed diagnosis of a non-TB lung condition (such as pneumonia, lung cancer, bronchitis, bronchiectasis, non-tuberculous mycobacterial disease, or chronic obstructive pulmonary disease), where the treating doctor has ruled out TB based on symptoms, imaging, and laboratory results
  • People aged 3 years or older, of any gender
  • People (or their guardian) who agree to take part and sign a consent form
  • People (or their guardian) who are able to attend follow-up visits as required by the trial

Who may not be able to join:

For general community members:

  • People with a known or suspected serious immune system disease or immune system damage or abnormality (HIV is an exception to this rule — confirm with trial site)
  • People who have recently used certain immune-suppressing medications (such as medium or high doses of steroid drugs like prednisone) or immune-boosting medications within 3 days before the skin test, where the trial doctor assesses this could affect results (certain low-dose, short-term, or topically applied steroids may be permitted — confirm with trial site)
  • People with a history of seizures, epilepsy, mental illness, or an immediate family member (parent, sibling, or child) with a history of mental illness
  • People with a history of strong allergic reactions, such as known allergies to two or more medications or foods, or a known allergy to any ingredient in the trial's test product
  • People currently experiencing an acute infectious illness (such as measles, whooping cough, or influenza), acute eye infection, acute ear infection, or widespread skin disease
  • People with a current fever, or who have taken fever-reducing, pain-relieving, or anti-allergy medicines within 3 days before the skin test, where the trial doctor assesses this could affect results
  • People with a severe skin infection (such as widespread infected skin sores or severe eczema)
  • People who have taken part in another clinical drug trial within the 3 months before the skin test (placebo, certain lab tests, or non-contact devices may be exceptions — confirm with trial site)
  • People who have received an inactivated vaccine within 7 days before the skin test, or a live vaccine within 28 days before the skin test
  • Women who are pregnant or breastfeeding, or women of childbearing age who test positive on a pregnancy test before joining
  • People with a history of drug abuse
  • People whose past medical history, physical examination results, or likelihood of not being able to follow the trial requirements the trial doctor believes could affect the trial results (for example, tattoos in the skin test area)
  • For the "triple-negative" sub-group only: people who have any reason they cannot receive a BCG vaccine, including immune deficiency (such as AIDS), current use of immune-suppressing drugs or radiation therapy, known allergy to BCG, current fever or acute infection (including active TB), or severe chronic illness affecting the heart, brain, blood vessels, or kidneys

For people with tuberculosis or non-TB lung disease:

  • People with a known or suspected serious immune system disease or immune system damage or abnormality (HIV is an exception — confirm with trial site)
  • People who have recently used certain immune-suppressing medications (such as medium or high doses of steroid drugs) or immune-boosting medications within 3 days before the skin test, where the trial doctor assesses this could affect results (certain low-dose, short-term, or topically applied steroids may be permitted — confirm with trial site)
  • People with a history of seizures, epilepsy, mental illness, or an immediate family member with a history of mental illness
  • People with a history of strong allergic reactions, such as known allergies to two or more medications or foods, or a known allergy to any ingredient in the trial's test product
  • People currently experiencing an acute infectious illness, acute eye infection, acute ear infection, or widespread skin disease
  • People with a severe skin infection (such as widespread infected skin sores or severe eczema)
  • People who have taken part in another clinical drug trial within the 3 months before the skin test (certain exceptions may apply — confirm with trial site)
  • People who have received an inactivated vaccine within 7 days before the skin test, or a live vaccine within 28 days before the skin test
  • Women who are pregnant or breastfeeding, or women of childbearing age who test positive on a pregnancy test before joining
  • People with a history of drug abuse
  • People whose past medical history, physical examination results, or likelihood of not being able to follow the trial requirements the trial doctor believes could affect the trial results (for example, tattoos in the skin test area)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 86+13611326573

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Chengdu CoenBiotech Co., Ltd
Registry
ClinicalTrials.gov
Start date
9 August 2025
Est. completion
1 May 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Sensitivity (true positive rate) of EEC and EC detection methods in tuberculosis patients aged 3 to 64 years; Specificity (true negative rate) of EEC and EC detection methods in patients with non-tuberculous lung diseases aged 3 to 64 years; Specificity (true negative rate) of EEC and EC for the diagnosis of Mycobacterium tuberculosis infection in healthy participants aged 3-64 years .; Negative rate of EEC test drug and TB-PPD control drug in BCG-vaccinated population in triple-negative population; Sensitivity (true positive rate) of EEC test drug versus control IGRA and TB-PPD for assisting...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov